| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25045d0ab18376cdf9c1a5b491374b9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5bc1605e77befd233420a0b00ca98a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a610296e6119693b60900bf957092f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a93d56e39bffcb3ed0aa0e226dadafe1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4c24a93f3cd84fa99b4eff7146559dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5a673a3b0ec3c951643e88dec58ff19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e09b355ecebb0f1ac8bd34e885cb9f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31ba5b95f48e7699cee25a09ebf8a26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e2893bfa485e714427af90bb68f0694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fa37ce70335d263783b00e3986c41de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13ad75f0fb49b581eac7dc0b2a1f95dc |
| publicationDate |
2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012007545-A1 |
| titleOfInvention |
Methods and kits for the diagnosis of prostate cancer |
| abstract |
The invention relates to methods and kits for the diagnosis of prostate cancer (PCa) in a subject, for assessing or monitoring the response to a therapy in a subject having PCa or for monitoring the progression of prostate cancer PCa based on the detection of alteration in the expression levels of at least one gene selected from the group of PC A3, PSMA and PSGR. The invention relates as well to methods for assessing whether a subject has to be subjected to a prostate biopsy, said subject having a serum PSA range within 4-10 ng/mL. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104531862-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104531863-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104531852-A |
| priorityDate |
2010-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |